Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Amyloid deposition in adults with drug-resistant temporal lobe epilepsy

  • Fonseca, Elena|||0000-0002-3895-1237
  • Lallana, Sofía|||0000-0002-5999-9889
  • Ortega, Gemma
  • Cano, Amanda|||0000-0001-9567-4283
  • Sarria Estrada, Silvana|||0000-0003-0083-362X
  • Pareto, Deborah|||0000-0001-7356-3769
  • Quintana, Manuel|||0000-0003-0288-9088
  • Lorenzo Bosquet, Carles|||0000-0002-8824-4602
  • López Maza, Samuel|||0000-0003-3660-2604
  • Gifreu, Ariadna
  • Campos Fernández, Daniel|||0000-0003-4795-5309
  • Abraira del Fresno, Laura|||0000-0002-5119-7929
  • Santamarina Perez, Estevo|||0000-0003-1915-0335
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Puerta, Raquel|||0000-0002-1191-5893
  • Aguilera, Núria
  • Ramis, Maribel
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Rovira, Alex|||0000-0002-2132-6750
  • Marquié, Marta|||0000-0002-0660-0950
  • Boada, Mercè|||0000-0003-2617-3009
  • Toledo, Manuel|||0000-0003-1550-3316
Objective: Pathological amyloid-β (Aβ) accumulation and hyperphosphorylated tau proteins have been described in resected temporal lobe specimens of epilepsy patients. We aimed to determine cerebrospinal fluid (CSF) Aβ1-42 and p181-tau levels and cerebral Aβ deposits on positron emission tomography (Aβ PET) and correlate these findings with cognitive performance in adults with drug-resistant temporal lobe epilepsy (TLE). Methods: In this cross-sectional study, we enrolled individuals with drug-resistant TLE who were 25-55 years old. Each participant underwent F-flutemetamol PET, determination of CSF Aβ1-42, p181-tau, and total tau, and a comprehensive neuropsychological assessment. We evaluated normalized standard uptake value ratios (SUVRs) for different brain regions on Aβ PET. Results: Thirty patients (mean age = 41.9 ± SD 8.1 years, 57% men) were included. The median disease duration was 9.5 (interquartile range = 4-24) years. Twenty-six patients (87%) had a clinically significant cognitive impairment on neuropsychological evaluation, 18 (69%) of the amnesic type. On Aβ PET, high uptake was observed in both mesial temporal regions (ipsilateral: SUVR z-score =.90, 95% confidence interval [CI] =.60-1.20; contralateral: SUVR z-score =.92, 95% CI =.57-1.27; p <.001), which was higher when compared to SUVR z-scores in all the remaining regions (p <.001) and in the ipsilateral anterior cingulate (SUVR z-score =.27, 95% CI =.04-.49, p =.020). No significant deposition was observed in other regions. Seven patients (23%) had low Aβ1-42 levels, and two (7%) had elevated p181-tau levels in CSF. Higher p181-tau levels correlated with poorer verbal fluency (R = -.427, p =.044). Significance: Our findings reveal a considerable Aβ deposition in mesial temporal regions and ipsilateral anterior cingulate among adults with drug-resistant TLE. Additionally, abnormal CSF Aβ1-42 levels were observed in a significant proportion of patients, and p181-tau levels were associated with verbal fluency. These results suggest that markers of neuronal damage can be observed in adults with TLE, warranting further investigation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Electrochemical biosensor for early Alzheimer's detection and patient risk stratification using plasma exosomes

  • Rossi, Rosanna|||0000-0002-3656-2908
  • Cano, Amanda|||0000-0001-9567-4283
  • Pallarès-Rusiñol, Arnau|||0000-0001-9990-148X
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Martí, Mercè|||0000-0002-1846-0043
  • Pividori, María Isabel|||0000-0002-5266-7873
Alzheimer's Disease (AD) is the leading cause of dementia, accounting for 60-70 % of cases worldwide. Early diagnosis remains challenging due to the limitations of current diagnostic tools, which are costly, invasive, and suffer from low patient compliance. Blood-based biomarkers, particularly plasma brain-derived exosomes (BDEs), have emerged as a promising alternative since they carry AD-related molecules and can be isolated non-invasively. In this study, an immunoassay was developed to isolate BDEs using magnetic particles functionalized with an anti-neuroligin-3 (NLGN3) antibody, while the AD-related marker β-secretase (BACE-1) was detected on the captured exosomes. This is the first report combining NLGN3 for for the isolation of BDEs with BACE-1 as a detection target, establishing a novel biomarker panel for AD diagnostics. The assay was evaluated across three readout platforms-optical, chemiluminescent, and electrochemical-with detection limits in the range of 104-105 exosomes μL-1. Among them, the portable electrochemical platform achieved the improved LOD (1.51 × 104 exosomes μL-1, R2 = 0.9829). Plasma samples from patients with AD, mild cognitive impairment (MCI), and healthy controls were analyzed, revealing differences in exosomal BACE-1 levels (p < 0.1, t-test). These findings demonstrate, for the first time, an in vitro diagnostic approach based on a portable electrochemical biosensor for early AD detection in plasma through a novel exosomal biomarker panel. Compared to conventional diagnostics, this biosensor offers a non-invasive and cost-effective solution for AD screening, with the potential to support earlier intervention and patient risk stratification.
Dipòsit Digital de Documents de la UAB
Publicación Artículo preliminar (WorkingPaper)

A peripheral proteomic signature of Alzheimer's disease is identified in the plasma extracellular vesicles of mild cognitive impairment patients from a memory clinic, the BIOPEXAL study

  • Capdevila-Bayo, Maria
  • Rossi, Rosanna|||0000-0002-3656-2908
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Puerta, Raquel|||0000-0002-1191-5893
  • Guzman, Laura
  • Carrasco Exposito, Marina|||0000-0001-8301-8000
  • Muñoz-Morales, Álvaro
  • Olivé Roig, Clàudia|||0000-0002-9438-5639
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • García-González, Pablo|||0000-0003-0125-5403
  • Bayón-Buján, Paula
  • Miguel-Romero, Andrea
  • Calm, Berta
  • Sotolongo Grau, Oscar|||0000-0002-9679-0670
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Tatinya, Natalia
  • Martínez, Marta
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Sanz Cartagena, Mª Pilar
  • Fernández, Mª Victoria
  • Marquié, Marta|||0000-0002-0660-0950
  • Valero, Sergi|||0000-0002-6599-948X
  • Montalban, Xavier|||0000-0002-0098-9918
  • Camins, Antoni|||0000-0002-1229-5956
  • Ramírez-Reveco, Alfredo|||0000-0003-4782-4261
  • Martí, Mercè|||0000-0002-1846-0043
  • Pividori, María Isabel|||0000-0002-5266-7873
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Ettcheto, Miren|||0000-0002-4301-7297
  • Cano, Amanda|||0000-0001-9567-4283
Aims: Alzheimer's disease (AD) is commonly diagnosed when neuronal damage is already established and irreversible. Achieving an accurate differential diagnosis in the preclinical and mild cognitive impairment (MCI) stage is one of the greatest challenges nowadays. Nanotechnological analysis of plasma extracellular vesicles (pEVs) are gaining attention as a promising tool for the early detection of AD pathology. This study aims to evaluate the proteomic profile of pEVs from patients with MCI and AD dementia to explore their potential as AD screening tools. Methods: pEVs were isolated by ultracentrifugation from 144 patients with MCI A-T-, MCI A+T+, and AD dementia. Nanoparticle tracking analysis and cryo-TEM were used to characterize the pEVs. CSF, serum and pEVs proteomics were carried out by using the multiplex PEA technology of Olink® proteomics, Inflammation and Neurology Explore 384 panels (768 proteins). Results: Characterization results showed that isolated plasma fraction corresponded in shape, size and concentration to EVs. Many pEVs neurology proteins involved in AD pathology significantly correlated (r > ± 0.30, p < 0.05) with their CSF homonyms, but not with their serum's. pEVs' proteome correlated with common AD signatures (CSF Aβ42 and pTau181, plasma pTau181, MMSE, NBACE, and Qalb) showing similar patterns to those observed with CSF biomarkers. Several pEVs neurology proteins didn't exhibit differences between the MCI A+T+ and AD dementia groups, whilst they did with MCI A-T-. Proteins in pEVs showed strong correlations with several measures of brain atrophy in MRI. Several neurology pEV proteins predicted conversion from MCI to AD dementia. Moreover, some of these showed a significant diagnostic accuracy of AD pathology. Conclusion: Preliminary results suggest that EVs biomarker signature could reflect AD pathology in the prodromal stages of AD continuum. However, further experiments are still needed for a better understanding of EVs' role in AD development and pathology dissemination.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment

  • Cano, Amanda|||0000-0001-9567-4283
  • Esteban de Antonio, Ester|||0000-0003-1965-6010
  • Bernuz, Mireia|||0000-0002-2052-6902
  • Puerta, Raquel|||0000-0002-1191-5893
  • García-González, Pablo|||0000-0003-0125-5403
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Olivé Roig, Clàudia|||0000-0002-9438-5639
  • Pérez-Cordón, Alba|||0000-0002-6028-0791
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Núñez-Llaves, Raúl|||0000-0002-6702-4774
  • Sotolongo Grau, Oscar|||0000-0002-9679-0670
  • Alarcón-Martín, Emilio|||0000-0002-0985-872X
  • Valero, Sergi|||0000-0002-6599-948X
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Martín, Elvira
  • Martino-Adami, Pamela V.
  • Ettcheto, Miren|||0000-0002-4301-7297
  • Camins, Antoni|||0000-0002-1229-5956
  • Vivas, Assumpta
  • Gómez Chiari, Marta|||0000-0001-6726-1721
  • Tejero, Miguel Ángel
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Marquié, Marta|||0000-0002-0660-0950
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Martí, Mercè|||0000-0002-1846-0043
  • Pividori, María Isabel|||0000-0002-5266-7873
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
In the clinical course of Alzheimer's disease (AD) development, the dementia phase is commonly preceded by a prodromal AD phase, which is mainly characterized by reaching the highest levels of Aβ and p-tau-mediated neuronal injury and a mild cognitive impairment (MCI) clinical status. Because of that, most AD cases are diagnosed when neuronal damage is already established and irreversible. Therefore, a differential diagnosis of MCI causes in these prodromal stages is one of the greatest challenges for clinicians. Blood biomarkers are emerging as desirable tools for pre-screening purposes, but the current results are still being analyzed and much more data is needed to be implemented in clinical practice. Because of that, plasma extracellular vesicles (pEVs) are gaining popularity as a new source of biomarkers for the early stages of AD development. To identify an exosome proteomics signature linked to prodromal AD, we performed a cross-sectional study in a cohort of early-onset MCI (EOMCI) patients in which 184 biomarkers were measured in pEVs, cerebrospinal fluid (CSF), and plasma samples using multiplex PEA technology of Olink© proteomics. The obtained results showed that proteins measured in pEVs from EOMCI patients with established amyloidosis correlated with CSF p-tau181 levels, brain ventricle volume changes, brain hyperintensities, and MMSE scores. In addition, the correlations of pEVs proteins with different parameters distinguished between EOMCI Aβ( +) and Aβ(-) patients, whereas the CSF or plasma proteome did not. In conclusion, our findings suggest that pEVs may be able to provide information regarding the initial amyloidotic changes of AD. Circulating exosomes may acquire a pathological protein signature of AD before raw plasma, becoming potential biomarkers for identifying subjects at the earliest stages of AD development.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Extracellular vesicles, the emerging mirrors of brain physiopathology

  • Cano, Amanda|||0000-0001-9567-4283
  • Ettcheto, Miren|||0000-0002-4301-7297
  • Bernuz, Mireia|||0000-0002-2052-6902
  • Puerta, Raquel|||0000-0002-1191-5893
  • Esteban de Antonio, Ester|||0000-0003-1965-6010
  • Sánchez-López, Elena|||0000-0003-2571-108X
  • Souto, Eliana B.
  • Camins, Antoni|||0000-0002-1229-5956
  • Martí, Mercè|||0000-0002-1846-0043
  • Pividori, María Isabel|||0000-0002-5266-7873
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
Extracellular vesicles are secreted by a wide variety of cells, and their primary functions include intercellular communication, immune responses, human reproduction, and synaptic plasticity. Their molecular cargo reflects the physiological processes that their cells of origin are undergoing. Thus, many studies have suggested that extracellular vesicles could be a promising biomarker tool for many diseases, mainly due to their biological relevance and easy accessibility to a broad range of body fluids. Moreover, since their biological composition leads them to cross the blood-brain barrier bidirectionally, growing evidence points to extracellular vesicles as emerging mirrors of brain diseases processes. In this regard, this review explores the biogenesis and biological functions of extracellular vesicles, their role in different physiological and pathological processes, their potential in clinical practice, and the recent outstanding studies about the role of exosomes in major human brain diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or brain tumors.